S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Immutep Stock Forecast, Price & News

-0.27 (-8.04%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
364,769 shs
Average Volume
565,137 shs
Market Capitalization
$263.86 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter.

Immutep logo

About Immutep

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.


Jefferies Financial Group Begins Coverage on Immutep (NASDAQ:IMMP)
December 2, 2021 |  americanbankingnews.com
Short Interest in Immutep Limited (NASDAQ:IMMP) Rises By 110.4%
November 30, 2021 |  americanbankingnews.com
Immutep Limited (NASDAQ:IMMP) Short Interest Up 83.0% in October
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.96 million
Book Value
$0.72 per share


Pretax Margin




Free Float
Market Cap
$263.86 million
Not Optionable

Company Calendar

Fiscal Year End


Overall MarketRank

1.66 out of 5 stars

Medical Sector

981st out of 1,388 stocks

Pharmaceutical Preparations Industry

461st out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Immutep (NASDAQ:IMMP) Frequently Asked Questions

Is Immutep a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immutep in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Immutep stock.
View analyst ratings for Immutep
or view top-rated stocks.

How has Immutep's stock price been impacted by Coronavirus?

Immutep's stock was trading at $2.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMMP stock has increased by 45.1% and is now trading at $3.09.
View which stocks have been most impacted by COVID-19

Are investors shorting Immutep?

Immutep saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 213,300 shares, an increase of 110.4% from the October 31st total of 101,400 shares. Based on an average trading volume of 373,700 shares, the days-to-cover ratio is currently 0.6 days.
View Immutep's Short Interest

What price target have analysts set for IMMP?

3 brokers have issued 12-month target prices for Immutep's shares. Their forecasts range from $8.00 to $9.00. On average, they anticipate Immutep's stock price to reach $8.43 in the next year. This suggests a possible upside of 172.9% from the stock's current price.
View analysts' price targets for Immutep
or view top-rated stocks among Wall Street analysts.

Who are Immutep's key executives?

Immutep's management team includes the following people:
  • Marc Voigt, Chief Executive Officer, CFO & Executive Director
  • Deanne Miller, COO, Secretary & General Counsel
  • David Fang, Finance Director & Assistant Secretary
  • Frédéric Triebel, Chief Scientific & Medical Officer
  • Christian Mueller, Vice President-Strategic Development

What other stocks do shareholders of Immutep own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT).

What is Immutep's stock symbol?

Immutep trades on the NASDAQ under the ticker symbol "IMMP."

Who are Immutep's major shareholders?

Immutep's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.49%), Morgan Stanley (1.46%), Renaissance Technologies LLC (0.26%), Verition Fund Management LLC (0.17%), Saturna Capital CORP (0.11%) and Belvedere Trading LLC (0.04%).

Which institutional investors are selling Immutep stock?

IMMP stock was sold by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, Millennium Management LLC, and Morgan Stanley.

Which institutional investors are buying Immutep stock?

IMMP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Belvedere Trading LLC, Toroso Investments LLC, Captrust Financial Advisors, Beirne Wealth Consulting Services LLC, Lindbrook Capital LLC, Jump Financial LLC, and Geode Capital Management LLC.

How do I buy shares of Immutep?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immutep's stock price today?

One share of IMMP stock can currently be purchased for approximately $3.09.

How much money does Immutep make?

Immutep has a market capitalization of $263.86 million and generates $2.96 million in revenue each year.

What is Immutep's official website?

The official website for Immutep is www.immutep.com.

Where are Immutep's headquarters?

Immutep is headquartered at LEVEL 12 95 PITT STREET, SYDNEY C3, 2000.

How can I contact Immutep?

Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at (128) 315-7003, via email at [email protected], or via fax at 61-2-8569-1880.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.